Efficacy Analysis of Monotherapy with Telitacicept in Immunoglobulin A Nephropathy Patients at High Progression Risk

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

Efficacy Analysis of Monotherapy with Telitacicept in Immunoglobulin A Nephropathy Patients at High Progression Risk

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Pei Zhang xingkong6662020@163.com Xi'an Gaoxin Hospital Nephrology Department Xi'an China *

Co-author 2

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

To observe the clinical efficacy of telitacicept monotherapy in a case of immunoglobulin A (IgA) nephropathy with high progression risk, and to explore the effect of telitacicept on IgA nephropathy.

Methods

A 31-year-old female patient was enrolled, who had suffered from proteinuria and elevated serum creatinine for 6 years. Pathological diagnosis via renal biopsy confirmed IgAnephropathy (Lee Classification: Grade Ⅳ; Oxford Classification: M1 E0 S1 T0 C1). She was initially treated with oral prednisone 30mg daily and a full dose of candesartan. Prednisone was discontinued after approximately 4 months of use. Multiple re-examinations showed that the 24-hour quantitative urinary protein remained >1g/day, indicating a high risk of IgA nephropathy progression. Considering the side effects of hormones and the patient's willingness, she was given telitacicept 160mg via subcutaneous injection once a week for a 3-month course. Changes in the patient's quantitative urinary protein, serum creatinine, and glomerular filtration rate were observed after telitacicept treatment, along with changes in lymphocyte count and percentage.

Results

After 12 weeks of treatment, the patient's 24-hour quantitative urinary protein decreased significantly, while serum creatinine and glomerular filtration rate remained stable.

Conclusion

For the treatment of IgA nephropathy with high progression risk, hormone and immunosuppressant have long been relied on. Although clinically effective, they are accompanied by extensive immunosuppression and side effects. Telitacicept achieves the therapeutic goal for IgA nephropathy by blocking the dual pathways of BLys and APRIL, thereby inhibiting the differentiation and maturation of B lymphocytes and reducing the production of pathogenic IgA. Meanwhile, it avoids the use of hormones and corresponding side effects, making it worthy of clinical recommendation. However, due to the small number of cases, further clinical verification is required.

Kewords